课题基金 / 基金详情

SUBOPTIMAL DRUG USE AND HEALTH OUTCOMES

SUBOPTIMAL DRUG USE AND HEALTH OUTCOMES
药物使用不理想和健康结果
批准号:
6055476
负责人:
JOSEPH T HANLON
金额:
$22.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-09-01 至 2001-08-31

项目摘要

项目成果

JOSEPH T HANLON的其他基金

相似基金

相关文献

中文摘要
翻译
该研究的目的是确定不适当的影响
英文摘要
The study's objective is to determine the impact of inappropriate prescribing on health-related outcomes for community dwelling elderly. Inappropriate prescribing is defined by two different criteria: 1) inappropriate medication use as defined by Beers et. al. (1991); 2) inappropriate medication use criteria developed under contract to HCFA in response to the Medicare Catastrophic Coverage Act of 1988. Outcomes measured include functional status (as measured by basic and instrumental activities of daily living, and mobility), health services utilization (hospitalization, institutionalization, emergency room and physician office visits) and associated costs, and mortality. Investigators plan to examine whether the relationship between inappropriate prescribing and outcomes are affected by factors such as age, gender, race, urban/rural residence and comorbidities. A longitudinal design that is population based will be used. The specific hypotheses to be tested are that, compared with elders not receiving inappropriate prescriptions, elderly participants with inappropriate prescribing will have greater functional decline, increased utilization of health services, higher costs and increased likelihood of death after controlling for important covarites (e.g. comorbidities). The study will analyze a pre-existing data set from the National Institute on Aging (NIA)-funded Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE).
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
UPITT Program for Pharmaceutical Outcomes Research in Aging
Racial Disparities in Older Adults: Impact of Medicare Part D
UPITT Program for Pharmaceutical Outcomes Research in Aging
UPITT Program for Pharmaceutical Outcomes Research in Aging
海外基金